About one in three people treated for major depressive disorder do not get adequate relief from two or more standard antidepressants. That number rarely comes up in a conversation with a primary care provider, which means many patients reach that point believing they have run out of options. The clinical designation for this pattern is difficult-to-treat depression, and it is a starting point for a different kind of evaluation, not an endpoint.
How Standard Antidepressants Work — and When They Don’t
The most commonly prescribed antidepressants fall into two main classes: selective serotonin reuptake inhibitors, known as SSRIs, and serotonin-norepinephrine reuptake inhibitors, known as SNRIs. SSRIs work by blocking the reabsorption of serotonin in the brain, increasing the amount of this neurotransmitter (a chemical messenger between nerve cells) available at synapses. SNRIs work through a similar mechanism but target both serotonin and norepinephrine, a second neurotransmitter involved in mood, energy, and alertness (National Institutes of Health).
These medications are effective for many patients and are considered first-line treatment for major depressive disorder because of their established safety and tolerability profiles (National Institutes of Health). When they work, they do so by modulating neurotransmitter availability in brain circuits involved in mood, concentration, sleep, and energy. That is a meaningful therapeutic action for a significant portion of patients.
The limitation is that they operate on a defined set of neurological pathways. Depression is not a single-mechanism condition, and when a patient does not respond to multiple SSRIs and SNRIs at appropriate doses, it often signals that the biology driving their depression may extend beyond those pathways.
Not every patient who has tried an antidepressant has completed what clinicians call an adequate trial. An adequate trial means taking the medication at a therapeutically appropriate dose for a sufficient duration, typically six to eight weeks at minimum. Patients often stop earlier because of side effects that appear before the medication has had time to work, or they are started on doses that are too low to produce a therapeutic effect. A medication stopped at week two after a low starting dose has not been given a genuine clinical test. This matters because the threshold for difficult-to-treat depression is two or more adequate trials without sufficient response.
Why Some Depression Resists Standard Treatment
When depression genuinely does not respond to two or more adequate antidepressant trials, there are several explanations worth considering.
Genetic variation in how a person metabolizes medications is one. Differences in the genes governing drug metabolism can mean a medication is cleared from the body too quickly to reach a therapeutic concentration, or that a patient is more likely to experience side effects at standard doses. Pharmacogenomic testing, meaning genetic testing that examines how a patient’s genes may affect their response to specific psychiatric medications, can help clarify these factors when there is reason to think they may be at play.
Underlying medical conditions are another contributor that is commonly missed. Thyroid dysfunction, sleep-disordered breathing, chronic inflammatory conditions, and nutritional deficiencies can all drive depressive symptoms through mechanisms that antidepressants do not directly address. Treating the depression without addressing these contributors produces incomplete results at best.
And in some cases, the neurological pathways most active in a given patient’s depression are not the ones standard antidepressants target. The glutamate system, which is the brain’s primary excitatory neurotransmitter network, has become a significant area of research and clinical focus in difficult-to-treat depression. Treatments that act on this system are available at Catalyst Psychiatry for patients who meet appropriate criteria.
Evaluating and Treating Difficult-to-Treat Depression in Corvallis
Difficult-to-treat depression is defined by treatment response, not by symptom severity. A patient with moderate depression that has not responded to two adequate antidepressant trials meets the clinical criteria. What patients with difficult-to-treat depression share more than any clinical criterion is the experience of trying — following prescriptions carefully, managing side effects, returning for follow-up, and still finding themselves in roughly the same place. That experience accumulates its own weight, and it is one we take seriously in every evaluation at Catalyst Psychiatry.
What a Thorough Evaluation Involves
The evaluation process at Catalyst Psychiatry for a patient presenting with difficult-to-treat depression is more detailed than a standard new patient intake. We review the full medication history, including dose, duration, and reason for stopping. We screen for medical contributors to depression. We assess for bipolar spectrum features, which can make standard antidepressants less effective and require a substantially different treatment approach. And in cases where genetic factors may be relevant, we discuss pharmacogenomic testing to examine whether those factors may have shaped prior medication outcomes.
Diagnosis at our practice is based on DSM-5 criteria (the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, the clinical standard for psychiatric diagnosis) and involves ongoing assessment rather than a single determination. The evaluation is the foundation of any treatment recommendation, and nothing is recommended before we understand the clinical picture clearly.
SPRAVATO® and Deep TMS: Options at Our Corvallis Practice
For patients who have not responded adequately to standard antidepressants, Catalyst Psychiatry offers evidence-based treatment options that work through different mechanisms. These are discussed with each patient individually, based on their history, diagnosis, and what they are looking for. Results vary by individual, and no single treatment is appropriate for every patient.
SPRAVATO® (esketamine nasal spray) is an FDA-approved treatment for adults with difficult-to-treat depression (the regulatory term is treatment-resistant depression) that targets NMDA receptors in the glutamate system rather than serotonin or norepinephrine pathways (U.S. Food and Drug Administration). It is administered in our Corvallis office under direct clinical supervision as part of a certified treatment program.
Deep TMS (Deep Transcranial Magnetic Stimulation) is an FDA-cleared, non-invasive treatment that uses magnetic pulses to stimulate areas of the brain involved in mood regulation. It does not involve medication and has no systemic side effects. Treatment takes place at our Corvallis office over a course of sessions.
The question of which, if either, may be appropriate for a specific patient is one we answer through evaluation and through a direct conversation about your history and goals. We are in-network with Providence, Pacific Source, First Choice Health, TriCare, Moda, Compsych, Samaritan Choice, Optum, UHC Commercial, United Behavioral Health, Triwest, and Regence Blue Cross Blue Shield. Insurance coverage for advanced treatments varies by plan, and we verify coverage before any treatment is recommended.
Frequently Asked Questions About Difficult-to-Treat Depression
How many antidepressants do I need to have tried to qualify as having difficult-to-treat depression?
The clinical threshold is two or more antidepressant medications taken at therapeutic doses for sufficient durations without adequate response. During an evaluation at Catalyst Psychiatry, we review each patient’s medication history in detail. A medication stopped early or never taken at a full therapeutic dose may not count as a complete trial. Understanding that history is part of what the evaluation is designed to clarify.
Does difficult-to-treat depression mean my depression cannot be treated?
No. Difficult-to-treat depression is a clinical description of how depression has responded to treatment so far, not a prognosis. The range of treatment options has expanded considerably, and most patients who come to us with this history have not exhausted the options available to them. Discuss what has and has not worked with your provider so that evaluation can proceed from a complete picture.
Could something other than my depression be making my antidepressants less effective?
Yes, and identifying those contributors is part of a thorough psychiatric evaluation. Thyroid dysfunction, sleep disorders, nutritional deficiencies, chronic inflammation, and bipolar spectrum features can all interfere with antidepressant response. Genetic factors affecting how you metabolize medications are also worth examining in some cases.
What is pharmacogenomic testing and do I need it?
Pharmacogenomic testing examines how your genes may affect your body’s ability to process and respond to specific medications. It can help identify whether genetic factors contributed to poor response or side effects with prior antidepressants. It does not predict with certainty which medication will work, but it can narrow the field and inform dosing decisions. At Catalyst Psychiatry, we discuss this option with patients for whom it may be clinically useful, not as a routine requirement.
What is the difference between SPRAVATO® and Deep TMS for difficult-to-treat depression?
SPRAVATO® is a nasal spray medication that targets the glutamate system and is administered in our office under supervision, while Deep TMS is a non-invasive device-based treatment that uses magnetic pulses to stimulate brain regions involved in mood regulation without medication. Both are available at Catalyst Psychiatry and have different mechanisms, treatment protocols, side effect profiles, and insurance coverage considerations. Which may be appropriate for a specific patient is a clinical determination made through evaluation and conversation with your provider. Results vary by individual for both.
Key Takeaways
- Difficult-to-treat depression is a clinical designation for depression that has not responded to two or more adequate antidepressant trials; it is a description of treatment history, not a prognosis.
- SSRIs and SNRIs are effective first-line treatments for many patients, but they act on specific neurotransmitter pathways; depression that persists through multiple adequate trials may involve systems those medications do not directly reach.
- A thorough psychiatric evaluation for difficult-to-treat depression includes reviewing the full medication history, screening for medical contributors, and assessing for factors that may have affected prior treatment response.
- Catalyst Psychiatry in Corvallis offers evidence-based treatment options for patients with difficult-to-treat depression, including SPRAVATO® and Deep TMS, evaluated and discussed individually based on each patient’s clinical picture.
- Results vary by individual; the evaluation is the starting point for determining which treatment approach, if any, is appropriate for a specific patient.
For patients in the Corvallis and Willamette Valley area who have been through antidepressant trials without adequate relief, the evaluation at Catalyst Psychiatry is where the clinical picture gets examined in full. We look at what you have tried, what may have affected those outcomes, and which treatment options are supported by the evidence and your specific history. Call us at 541-730-4400 or reach out through our website to schedule an evaluation. The decision about what to pursue is yours, and our role is to give you the honest clinical picture you need to make it.
References
National Institutes of Health. Selective serotonin reuptake inhibitors: pharmacology, clinical efficacy, and tolerability. https://pmc.ncbi.nlm.nih.gov/articles/PMC8395812/
National Institutes of Health. Serotonin-norepinephrine reuptake inhibitors: a review of clinical efficacy, tolerability, and safety. https://pmc.ncbi.nlm.nih.gov/articles/PMC8544373/
Johnson & Johnson. SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression. https://www.jnj.com/media-center/press-releases/spravato-esketamine-approved-in-the-u-s-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression
Medical Disclaimer: The information in this blog is for educational purposes only and does not constitute medical advice. Treatment for depression, including advanced options such as SPRAVATO® and Deep TMS, should only be pursued under the supervision of a licensed psychiatric provider familiar with your full medical and psychiatric history. Individual results vary. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline, or go to your nearest emergency room.